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Abstract: A bicyclic peptide scaffold was chemically adapted
to generate diarylethene-based photoswitchable inhibitors of
serine protease Bos taurus trypsin 1 (T1). Starting from
a prototype molecule—sunflower trypsin inhibitor-1 (SFTI-
1)—we obtained light-controllable inhibitors of T1 with Ki in
the low nanomolar range, whose activity could be modulated
over 20-fold by irradiation. The inhibitory potency as well as
resistance to proteolytic degradation were systematically
studied on a series of 17 SFTI-1 analogues. The hydrogen
bond network that stabilizes the structure of inhibitors and
possibly the enzyme–inhibitor binding dynamics were affected
by isomerization of the photoswitch. The feasibility of
manipulating enzyme activity in time and space was demon-
strated by controlled digestion of gelatin-based hydrogel and
an antimicrobial peptide BP100-RW. Finally, our design
principles of diarylethene photoswitches are shown to apply
also for the development of other serine protease inhibitors.
The use of light to control functions of biomacromolecules
has become an active field of research over the last decades.
Reversibly photoisomerizable (i.e. photoswitchable) com-
pounds have already demonstrated great promise in medic-
inal chemistry[1] and materials science.[2] Particular attention
has been devoted to control the activity of enzymes by light,[3]
as enzymes are important drug targets[4a] and often are
components of “smart” soft materials.[4b,c] Most of the known
photocontrollable enzyme inhibitors have been designed
using two general strategies, illustrated in Figure 1. One
(Figure 1A) is based on the incorporation of a photoisomer-
izable fragment (photoswitch) into a known inhibitor as part
of the enzyme-binding moiety. This strategy is well-suited for
the design of small-molecule constructs; many photocontrol-
lable, mostly azoarene-derived inhibitors[5a–d] of this type have
been reported, although other types of photoswitches were
also used.[5e–h] Another successful approach consists of design-
ing so-called “two-pronged” inhibitors, in which the photo-
switching unit connects two target-binding moieties (Fig-
ure 1B). Efficient diarylethene (DAE)[6] and azobenzene-
modified[7] enzyme modulators with two distinct binding sites
have been prepared using this second approach. Here, we
introduce yet another design—grafting the target-binding and
the photoswitching moieties onto opposing loops of a macro-
bicyclic scaffold (Figure 1 C). In this case, the constructs have
the binding and photoregulating units joined through a bridge
in the bicycle.
We were inspired by success in using bicyclic scaffolds for
design of non-photocontrollable multifunctional peptides. For
example, Pei et al. reported recently on bicyclic cell-perme-
able PIN-1 inhibitors,[8] in which the enzyme-binding and cell-
penetrating units were joined through a bicyclic peptide core.
Figure 1. General design strategies of photoswitchable enzyme inhib-
itors. The moieties directly binding to enzymes are schematically
shown in blue, the photoswitch is shown in red.
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Although the photoswitch moiety is distant to the binding unit
in our constructs, we demonstrate here that both units can
“communicate” through the bicyclic scaffold, resulting in
efficient photomodulation.
With the suggested strategy, we designed and optimized
DAE-based peptidic inhibitors of chymotrypsin-like (S1)
serine proteases, the largest family of all peptidases.[9] Serine
proteases have a broad biological significance and immense
potential as drug targets, as their malfunction is linked to
numerous pathologies.[10] These enzymes have been in the
focus of intensive research directed towards the discovery of
new inhibitors,[11] including photocontrollable ones.[12] The
latter were based exclusively on azobenzenes as the photo-
switching moiety; no DAE-derived inhibitors have been
reported to date for this class of enzymes.
Bos taurus trypsin 1 (T1) represents the S1 family by its
catalytic mechanism, inhibitor susceptibility profile and
substrate specificity, and was thus selected as the model
target.[9] As the reference compound and as the starting
template, we used the sunflower trypsin inhibitor-1 (SFTI-1).
It is bicyclic, well-studied and is one of the strongest natural
inhibitors of trypsin-like endopeptidases (Ki 0.1–3.4 nm for
T1).[13] The SFTI-1 molecule has two antiparallel b-strands
stabilized by a disulfide bridge (Figure 2).[14]
When designing the analogues of the SFTI-1, we relied on
the known mechanism of inhibition and the relationship
between structure and activity of SFTI-1.[9, 15] We also
considered the changes in molecular dynamics that the
diarylethene moiety causes upon photoisomerization.[5e, 16]
SFTI-1 inhibits trypsin by the Laskovski mechanism,[17] that
is, it binds tightly to the protease (Figure 2A) but resists
hydrolysis, thereby blocking the enzyme. The resistance to
hydrolysis has been attributed[13a, 14a,18] to a rigid bicyclic
structure and a tight network of hydrogen bonds (Figure 2B).
Modifications of the reactive loop are known to drastically
deteriorate the inhibitory activity, while the structural loop
can be modified without substantial activity drop.[13a,19]
Therefore, we incorporated the photoswitch within the
structural loop of SFTI-1, using building block 1 (Figure 3)
developed previously by us.[20] We aimed at the compounds in
which the ring-open DAE fragment would cause minor
changes in the enzyme inhibition, while the ring-closed
DAE photoform would minimize this activity.
The first series of DAE-containing SFTI-1 analogues
(S1n, S2–S4, Table 1) was prepared to explore the impact of
the structural loop size upon the inhibitory activity and
photoswitching efficiency, and to check the role of the bridge
on the functionality of the entire construct. As can be seen
from the data in Table 1, compound S1n proved to be a strong
T1 inhibitor, comparable to SFTI-1. However, this peptide
could not be converted to the ring-closed form, presumably
because of severe constraints in the structural loop due to its
small size.[21] The analogue S2, lacking the bridge, was well
photoisomerizable. (See the data about the photostationary
state under UV irradiation for all the compounds studied here
in the SI. Conversion from ring-closed forms to the ring-open
forms under visible light irradiation (at 570 nm) was in all
cases practically quantitative.) However, we observed a sig-
nificant drop in its activity compared to the native inhibitor.
The smaller bridge-free analogue S3 also showed a reduced
activity. Besides, it was obtained with a very low yield at the
cyclization step. The smallest bridge-free analogue S4 (ring-
open), although being a potent inhibitor, also did not
photoisomerize into the ring-closed form. These results
from the first series suggest that incorporation of the DAE
into the structural loop of SFTI-1 may indeed result in potent
T1 inhibitors. However, more conformational freedom should
be provided in the structural loop to enable effective photo-
isomerization, and the bridge should be kept in place.
We hypothesized that an extension of the bridge might
provide the required freedom. Replacement of the disulfide
bond in SFTI-1 with surrogates has been described in the
literature.[22] The majority of such substitutions were func-
tionally tolerated, providing a significant increase in the
redox-stability. Hence, we designed the second series of
analogues with elongated bridges (S5n–S7n, Table 1).
The proteolytic stability of the peptide inhibitors is the
second major factor, besides Ki, that is of importance for any
practical utility.[19d,23] The hydrolysis rate does not strictly
correlate with Ki but depends on the activation barrier of the
hydrolysis reaction.[24] It is known that T1 may cleave SFTI-
1 at Arg2 in the structural loop. Since neither Arg2 nor Phe12
have been reported as critical in binding to trypsin,[19a] we
supplemented the second series of SFTI-1 analogues by
“inverted” compounds. Here, Arg2 and Phe12 were swapped
in order to evaluate the effect of Arg2 on the proteolytic
stability (S1i, S5i–S7i, Table 1). As anticipated, all analogues
with elongated bridges (S5n–S7n, S5i–S7i) were photoisomer-
izable. Generally, upon extending the bridge, the potency and
stability of the peptides decreased. At the same time, we
Figure 2. Sequence, nomenclature and structure of SFTI-1. A) Sche-
matic representation of the SFTI-1 peptide and its structural/functional
parts. B) Molecular structure and hydrogen bonding network (PDB:
1JBL).[14a]
Figure 3. DAE-containing amino acid used to prepare the SFTI-1 ana-
logues, and nomenclature of the photoisomers.
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Table 1: T1 inhibitors studied in this work.[a]















SFTI-1 3.40.2 – 2.00.1  105 –
SFTI-1i 12.50.8 – 2.00.2  105 –
First series of inhibitors
S1n 4.90.3 – – 7.80.2  105 – –
S2 2036 65933 3.2 – – –
S3 1019 – – – – –
S4 223 – – – – –
Second series
S1i 13.41.4 – – 8.30.3  105 – –
S5n 956 23114 2.4 2.50.1  103 3.40.5  102 13.6
S5i 10214 18216 1.8 2.90.1  103 5.00.8  103 1.7
S6n 1358 1120109 8.3 6.70.9  103 2.50.8  102 3.7
S6i 44143 7700600 17.5 1.90.1  102 1.10.2  101 5.8
S7n 63.44.4 2200214 34.7 2.00.2  103 6.11.2  102 30.5
S7i 26330 7220360 27.5 7.50.2  103 5.51  101 73
Third series
S8n 5.20.4 1258 24 1.30.7  104 5.31.4  104 4.1
S9n 8.30.6 553.8 6.6 1.50.3  104 1.30.1  103 8.7
S10n 17.50.7 1817 10.3 2.30.2  104 3.60.3  103 15.7
S10i 5.10.4 44.82.2 8.8 5.30.4  105 2.20.3  104 4.2
S11i 1720130 5370420 3.1 2.80.3  102 9.11  102 3.3
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observed a systematic increase in the activity difference
between the ring-open and ring-closed forms. We also found
that the Arg2/Phe12 inversion improved the proteolytic
stability of some analogues.
In the third series of photoswitchable SFTI-1 analogues,
we explored the extension of the peptide cycles. One or two
additional aliphatic residues (Val and Leu) were introduced at
the flanks of the photoswitch (S8n–S10n, S10i, Table 1). Two
triazole-linked analogues (S11i, S12i) bearing elongated
bridges were also prepared. This design yielded the best
photoswitchable analogues, which not only retained a high
inhibitory potency in the low nanomolar range, but also
showed efficient photoswitching of their activity. Compound
S8n, which is the best performing molecule in terms of
inhibitory potency and photoswitching efficiency of the
inhibiting activity, was found to change its Ki from 5.2 to
125 nm upon photoisomerization, that is, by a factor of 24. The
hydrolysis rates for the disulfide-bearing inhibitors of this
series were close to that for native SFTI-1. The triazole-
bridged S11i and S12i, however, showed a drastic loss of
activity as well as proteolytic stability.
Structural preorganization—resulting in a low entropic
penalty upon enzyme binding—was postulated to be the key
factor determining the high potency of SFTI-1.[13a] To under-
stand the mechanism by which the DAE photoswitch in our
compounds modulates the Ki and hydrolysis rate, we mea-
sured hydrogen/deuterium exchange rates for the compounds
in D2O using MALDI mass spectrometry. From these data,
the number of hydrogen bonds could be quantified and
compared with the values obtained for Ki and kH.
[25] Figure 4
illustrates the relationship between conformational stability
in terms of the number of protons in slow exchange,
proteolytic stability, and the potency of each inhibitor/photo-
isomeric state. The prototype SFTI-1 and its “inverted”
mutant SFTI-1i possessed 7.0 slow-exchanging protons (t1/2>
40 s). The best-performing analogues S8n, S9n, S10n, and S10i
had a comparable number of slow-exchanging protons in their
ring-open forms (5.5 to 6.5), but far less upon photoswitching,
which correlated well with their Ki and kH. This correlation
provides evidence that the ring-open DAE facilitates preor-
ganization of the reactive loop through hydrogen bonds,
which stabilize the conformation and enhance the potency.
The structure–activity relationship of the entire library is
not as straightforward, however. Compound S6i, for example,
has approximately the same number of exchanging protons
for its two photoforms (approx. 3.4), yet its Ki and kH changed
significantly upon photoisomerization (Figure 4). Although
an influence of the DAE moiety on the structural preorga-
nization of the S6i molecule cannot be excluded, it appears
more probable that the DAE photoswitching modulates the
dynamics of the enzyme–inhibitor complex. The DAE is
expected to significantly influence the dynamics, because this
photoswitch possesses a very different flexibility in its two
photoforms. The more flexible ring-open peptides can thus
have more favorable conformational and vibrational entropy
changes upon binding to the target protein than the corre-
sponding ring-closed photoforms.[16]
SFTI-1 serves as a lead in developing inhibitors of other
serine proteases.[22c,e, 23b,26] To demonstrate that our photo-
switchable T1 inhibitors can be modified to inhibit other
members of the chymotrypsin-like family, we synthesized S5F,
an analogue of S10n in which Lys5 at the P1 position was
changed to Phe. Such modification in the native SFTI-1 had
been reported to result in a potent inhibitor of a-chymotryp-
sin. A non-photoswitchable mutant SFTI-5F was taken as
a control, whose Ki value was measured to be 2.8 nm. As
expected, S5F inhibited a-chymotrypsin (from bovine pan-
creas Type II) very well. The Ki values of the two photo-
isomers differed by 21-fold (5.8 nm for the ring-open form,
122 nm for the ring-closed form), proving that the present
scaffold can be adapted to inhibit other serine proteases in the
Table 1: (Continued)














S12i 2440215 12400900 5.0 1.40.3  102 4.20.4  102 3.0
[a] T1 inhibitory activities (Ki), T1-induced hydrolysis rate constants (kH), and their ratio for the ring-closed to the ring-open isomers. The residue of 1 is
highlighted by red color and underlined.
Figure 4. Relationship between T1 inhibitory activity, proteolytic stabil-
ity, and the number of slow-exchanging protons in the photoswitchable
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same photocontrollable manner. We also wondered how
selective our inhibitors were and characterized S5F against
trypsin and its prototype S10n (one of the best-performing
trypsin inhibitors) against a-chymotrypsin. As expected, only
weak inhibition with IC50 values at 50–100 mm (> 3 orders of
magnitude lower compared to their parent proteases inhib-
ition) was observed in each case, proving sufficient enzyme
selectivity of our compounds.
Finally, photostability in repeated cycles of reversible
photoisomerization was studied on three selected compounds
(linear Ac-Ala-1-Ala-NH2, peptide S2 lacking the bridge, and
S10i). All three compounds demonstrated moderate photo-
fatigue resistance in these tests (see the SI) degrading less
than 30 % in 15 cycles. We consider this acceptable for most
biomedical applications, where only one or a few cycles of the
photoconversion are usually needed.[1–3]
To demonstrate the manipulation of the enzyme activity
in space and time by light, we set up two experiments. The
first one was based on digestion of a gelatin-based hydrogel
with trypsin. A water solution of gelatin (20 mgmL1) was
mixed with S10n (ring-closed form) and trypsin (10 mm and
100 nm final concentrations, respectively). Bromophenol blue
was added for better visualization of the gel, which was
formed in a Petri dish at 0 8C in the dark. The light (approx.
10 mW cm2) was then applied for 3 min to the gel trough
a mask to convert S10n to the ring-open form, an active
trypsin inhibitor. Incubation of the Petri dish at 20 8C after the
irradiation resulted in liquefying of the gel only in places
where the light did not reach the mixture. The liquid was
removed, leaving the intact areas where trypsin was inhibited
by the photoactivated S10n (Figure 5; an image of the whole
Petri dish after the experiment can be seen in the Table of
Contents picture).
An analogous experiment was designed to show the
photoregulation of BP100-RW peptide activity by digestion
with trypsin. BP100-RW (sequence RRLFRRILRWL-NH2)
is known as a potent antimicrobial peptide (AMP).[27] Growth
of E. coli DSM 498 was monitored in a media containing the
peptide (64 mg mL1, twice as high as the minimal inhibitory
concentration), trypsin (3 nm), and S10n ring-closed (300 nm).
Irradiation of the mixture prevented the bacterial growth,
while the bacteria grew almost as fast as without the BP100-
RW in a control experiment in dark (Figure S9).
In summary, we have evaluated a strategy for the design of
efficiently photocontrollable bicyclic peptide-based enzyme
inhibitors. Our compounds possess the enzyme-binding frag-
ment in one cyclic unit, and the photoswitchable fragment in
the opposite cyclic unit of the macro-bicycle. We used the
diarylethene photoswitch for effective regulation of inhibiting
activity of serine proteases, which has never been used before
for this class of enzymes and demonstrated the utility of the
obtained enzyme inhibitors for photoregulation of hydrogel
digestion and antibacterial activity of an AMP. These results
pave the way for the development of new macro-bicyclic
inhibitors of other chymotrypsin-like family proteases, in
particular, taking natural serine protease inhibitors as the
templates.
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